Radiopharm Theranostics (RAD) TD Cowen 45th Annual Healthcare Conference summary

Corporate and strategic overview

• Dual-listed on ASX and Nasdaq since December 2024, with a $60 million market cap and 65% institutional ownership.

• Lantheus increased its stake to 12%, validating the company's radiopharmaceutical focus.

• Five U.S. biotech funds joined as investors in June, further strengthening institutional backing.

• R&D operations leverage Australian clinical trials for a 43% R&D rebate, optimizing non-dilutive funding.

Pipeline and clinical development

• Seven molecules in the pipeline: four in clinical stage, three in late preclinical, with a focus on oncology targets.

• Top three assets: PD-L1 and HER2 nanobody therapeutics (Lutetium-177 labeled) and an F-18 pivalate imaging agent for brain metastases.

• Additional programs include integrin αvβ6, B7-H3, and KLK3, with INDs targeted for mid-2024 and second-half clinical entry.

• KLK3 program uses Terbium-161, an emerging isotope with dual emission properties for enhanced therapeutic effect.

Clinical trial progress and timelines

• PD-L1 radiopharmaceutical is the first of its kind in clinical stage, with phase 1 basket trial across six tumor types; interim data expected June–July, trial completion by year-end.

• HER2 nanobody trial began after imaging validation, targeting post-ADC patients; first dosing expected in March, interim data by year-end, trial completion by June 2026.

• F-18 pivalate imaging agent for brain metastases in phase 2B, with first patient dosing imminent and interim data mid-year.